ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a
leading late clinical-stage cellular therapeutics company focused
on chronic kidney disease (CKD), today announced that the Company
will present four posters discussing investigations into the
mechanism of action and clinical outcomes observed with REACT®
(rilparencel) at the upcoming American Society of Nephrology’s
(ASN) Kidney Week being held on November 2-5, 2023, in
Philadelphia, PA.
The titles for the accepted abstracts are provided below and
accessible online at:
https://www.asn-online.org/education/kidneyweek/2023/program-search-abstract.aspx.
ASN Kidney Week attendees are also invited to visit the
ProKidney booth (#938) during exhibit hours for additional
information on REACT®.
Poster Presentations
Renal autologous cell therapy (REACT) to delay dialysis
in advanced CKD Session Title: Diabetic Kidney Disease:
Clinical - ISession Date & Time: November 2, 2023, from 10:00
AM to 12:00 PM EDTPoster Board #: TH-PO169
Selected Renal Cells Express a Podocyte-Parietal
Epithelial Cell Transcriptome Session Title: Glomerular
Diseases: Podocyte Biology - ISession Date, Time: November 2, 2023,
from 10:00 AM to 12:00 PM EDTPoster Board #: TH-PO739
Selected Renal Cells Exhibit Renal Tubule Formation
Associated with Transforming Growth Factor B2 Expression
Session Title: Pediatric Nephrology - IISession Date, Time:
November 3, 2023, from 10:00 AM to 12:00 PM EDTPoster Board #:
FR-PO637
Selected Renal Cells Improve Renal Function in a Canine
Model of Chronic Kidney DiseaseSession Title: Development,
Organoids, Vascularized Kidneys, Nephrons, and MoreSession Date,
Time: November 4, 2023, from 10:00 AM to 12:00 PM EDTPoster Board
#: SA-PO354
Publication Only
Osteopontin-Associated Reparative Effects of Selected
Renal CellsAbstract: PUB085
Selected Renal Cells Express Cell Adhesion Markers and
Form Renal TubulesAbstract: PUB086
Following the event, a copy of the poster presentations will be
available on the Company’s website at
https://investors.prokidney.com/news-events/events-and-presentations.
Additional information on ASN Kidney Week 2023 can be accessed
online at https://www.asnonline.org/education/kidneyweek/.
About ProKidneyProKidney, a pioneer in the
treatment of CKD through innovations in cellular therapy, was
founded in 2015 after a decade of research. ProKidney’s lead
product candidate, REACT® (Renal Autologous Cell Therapy), is a
first-of-its-kind, patented, proprietary autologous cellular
therapy being evaluated to potentially preserve kidney function in
diabetic patients at high risk of kidney failure. REACT has
received Regenerative Medicine Advanced Therapy (RMAT) designation,
as well as FDA and EMA guidance, supporting its ongoing Phase 3
clinical program that launched in January 2022. For more
information, please visit www.prokidney.com.
Forward-Looking StatementsThis press release
includes “forward-looking statements” within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995. ProKidney’s actual results may differ from its
expectations, estimates and projections and consequently, you
should not rely on these forward-looking statements as predictions
of future events. Words such as “expect,” “estimate,” “project,”
“budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,”
“will,” “could,” “should,” “believes,” “predicts,” “potential,”
“continue,” and similar expressions (or the negative versions of
such words or expressions) are intended to identify such
forward-looking statements. These forward-looking statements
include, without limitation, the Company’s expectations with
respect to financial results and expected cash runway, future
performance, development and commercialization of products, if
approved, the potential benefits and impact of the Company’s
products, if approved, potential regulatory approvals, the size and
potential growth of current or future markets for the Company’s
products, if approved, the advancement of the Company’s development
programs into and through the clinic and the expected timing for
reporting data, the making of regulatory filings or achieving other
milestones related to related to the Company’s product candidates,
and the advancement and funding of the Company’s developmental
programs generally. Most of these factors are outside of the
Company’s control and are difficult to predict. Factors that may
cause such differences include, but are not limited to: the
inability to maintain the listing of the Company’s Class A ordinary
shares on the Nasdaq; the inability to implement business plans,
forecasts, and other expectations or identify and realize
additional opportunities, which may be affected by, among other
things, competition and the ability of the Company to grow and
manage growth profitably and retain its key employees; the risk of
downturns and a changing regulatory landscape in the highly
competitive biotechnology industry; the inability of the Company to
raise financing in the future; the inability of the Company to
obtain and maintain regulatory clearance or approval for its
products, and any related restrictions and limitations of any
cleared or approved product; the inability of the Company to
identify, in-license or acquire additional technology; the
inability of Company to compete with other companies currently
marketing or engaged in the biologics market and in the area of
treatment of kidney diseases; the size and growth potential of the
markets for the Company’s products, if approved, and its ability to
serve those markets, either alone or in partnership with others;
the Company’s estimates regarding expenses, future revenue, capital
requirements and needs for additional financing; the Company’s
financial performance; the Company’s intellectual property rights;
uncertainties inherent in cell therapy research and development,
including the actual time it takes to initiate and complete
clinical studies and the timing and content of decisions made by
regulatory authorities; the fact that interim results from our
clinical programs may not be indicative of future results; the
impact of COVID-19 or geo-political conflict such as the war in
Ukraine on the Company’s business; and other risks and
uncertainties included under the heading “Risk Factors” in the
Company’s most recent Annual Report on Form 10-K, subsequent
Quarterly Reports on Form 10-Q and other filings with the
Securities and Exchange Commission. The Company cautions readers
that the foregoing list of factors is not exclusive and cautions
readers not to place undue reliance upon any forward-looking
statements, which speak only as of the date made. The Company does
not undertake or accept any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
to reflect any change in its expectations or any change in events,
conditions or circumstances on which any such statement is
based.
Contacts:
Corporate:Glenn Schulman, PharmD, MPHSVP, Investor
Relationsglenn.schulman@prokidney.com
Investors:Burns McClellanLee Roth / Julia
Weilmanlroth@burnsmc.com / jweilman@burnsmc.com
Media:Burns McClellanSelina Husain / Robert Flamm,
Ph.D.shusain@burnsmc.com / rflamm@burnsmc.com
ProKidney (NASDAQ:PROK)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
ProKidney (NASDAQ:PROK)
Gráfica de Acción Histórica
De May 2023 a May 2024